FCMA
IBB icon

Foresight Capital Management Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Foresight Capital Management Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-522
Closed -$68K – 79
2022
Q1 		$68K Buy
522
+9
+2% +$1.17K 0.08% 59
2021
Q4 		$78K Buy
+513
New +$79.4K 0.08% 64

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Foresight Capital Management Advisors's IBB Position: Q2 2022 in Review

Foresight Capital Management Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 522 shares — an estimated $68K sold.

Foresight Capital Management Advisors first reported a position in IBB in Q4 2021 and held it in 2 quarters. The position peaked at $78K in Q4 2021. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

  • Foresight Capital Management Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
  • Foresight Capital Management Advisors sold 522 iShares Biotechnology ETF shares in Q2 2022, an estimated $68K.
  • Foresight Capital Management Advisors first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 2 quarters.
  • Foresight Capital Management Advisors's iShares Biotechnology ETF position peaked at $78K in Q4 2021.
  • 858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Foresight Capital Management Advisors's 13F filing for Q2 2022, filed 11 Jul 2022.